These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31534084)

  • 21. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
    J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
    Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
    J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program.
    Masarone M; Caruso R; Aglitti A; Izzo C; De Matteis G; Attianese MR; Pagano AM; Persico M
    Dig Liver Dis; 2020 May; 52(5):541-546. PubMed ID: 32234417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cascade of care for children and adolescents with chronic hepatitis C.
    Rogers ME; Balistreri WF
    World J Gastroenterol; 2021 Mar; 27(12):1117-1131. PubMed ID: 33828389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
    Rojas Rojas T; Di Beo V; Delorme J; Barre T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B; Marcellin F
    Int J Drug Policy; 2019 Oct; 72():61-68. PubMed ID: 31129024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C Virus in Pregnancy: An Opportunity to Test and Treat.
    Fogel RS; Chappell CA
    Obstet Gynecol Clin North Am; 2023 Jun; 50(2):363-373. PubMed ID: 37149316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.
    Hirosawa T; Morimoto N; Miura K; Tahara T; Murohisa T; Okamura Y; Sato T; Numao N; Imai M; Tano S; Murayama K; Kurata H; Ozawa I; Fukaya Y; Yoshizumi H; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
    Intern Med; 2019 Feb; 58(4):477-485. PubMed ID: 30333396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil.
    Carvalho-Louro DM; Soares EB; Trevizoli JE; Marra TMG; da Cunha ALR; Rodrigues MP; Carvalho-Furtado ACL; Dos Santos BTA; de Assis da Rocha Neves F
    BMC Infect Dis; 2020 Feb; 20(1):114. PubMed ID: 32041537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass screening for hepatitis B and C in Southern Upper Egypt.
    Soliman G; Elzalabany MS; Hassanein T; Miller FD
    BMC Public Health; 2019 Oct; 19(1):1326. PubMed ID: 31640639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    Traeger MW; Pedrana AE; van Santen DK; Doyle JS; Howell J; Thompson AJ; El-Hayek C; Asselin J; Polkinghorne V; Membrey D; Bramwell F; Carter A; Guy R; Stoové MA; Hellard ME;
    PLoS One; 2020; 15(6):e0235445. PubMed ID: 32603349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
    Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
    Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.
    Wang AE; Hsieh E; Turner BJ; Terrault N
    J Gen Intern Med; 2022 Oct; 37(13):3435-3443. PubMed ID: 35484367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017-2019 Mass Screening and Treatment Campaign.
    Nisingizwe MP; Makuza JD; Janjua NZ; Bansback N; Hedt-Gauthier B; Serumondo J; Remera E; Law MR
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.